New combo attack on tough liver cancers shows promise in early trial
NCT ID NCT07268131
First seen Jan 06, 2026 · Last updated Jun 18, 2026 · Updated 22 times
Summary
This study tests a new approach for people with liver cancer that is too advanced for standard transplant criteria but can still be surgically removed. Participants will receive a liver-directed treatment (TACE) combined with an immunotherapy drug (QL1706) before surgery, and continue the immunotherapy after surgery. The goal is to see if this combination can shrink the tumor enough to improve outcomes, and to find markers that predict who benefits most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.